How Did These Two ASX Stocks, Greenwing Resources (ASX:GW1) and AVITA Medical (ASX:AVH), Gain Over 300% in a Year?

Sonal Goyal

01 November 2026 01:51 AM AEDT

How Did These Two ASX Stocks, Greenwing Resources (ASX:GW1) and AVITA Medical (ASX:AVH), Gain Over 300% in a Year?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Greenwing Resources (ASX:GW1) was quoted at AUD 0.12, up around 300% in one year, on 30 October 2026.
AVITA Medical (ASX:AVH) was quoted at AUD 4.69 on the same date, with a reported one-year rise of 307%.
The companies operate in different sectors: critical minerals exploration and acute wound-care technology.

Two ASX-listed companies showed reported one-year share-price gains of approximately 300% or more in quotes recorded on 30 October 2026. Greenwing Resources Ltd (ASX:GW1) was quoted at AUD 0.12 at about 4:13 pm AEDT, up around 300% from a year earlier, while AVITA Medical Inc (ASX:AVH) stood at AUD 4.69 at about 4:12 pm AEDT, up approximately 307%. Greenwing develops critical-minerals projects; AVITA markets therapeutic wound-care technologies.

Greenwing: Lithium and Polymetallic Project Work

Greenwing's 28 October 2026 quarterly activities report covered the period ended 30 September 2026. At its San Jorge lithium project in Argentina, the company continued a scoping study involving Basin hydrology, processing Options and direct lithium extraction. Several pilot partners were chosen following assessment of more than 30 suppliers. They will evaluate representative brines, with findings intended to inform the processing route and preliminary economics. Greenwing separately described a strategic-investor process involving Due Diligence by prospective partners, without announcing a concluded financing agreement.

At Que River in Tasmania, Greenwing continued a pre-feasibility study covering potential renewed mining, nearby third-party processing and related approvals. It also assessed a separate data-infrastructure possibility. The company forecast study completion in the first calendar quarter of 2027. Graphmada, its graphite project in Madagascar, remained on care and maintenance. These projects differ in mineral focus, Maturity and commercial pathway.

Greenwing: Cash Position and Funding Questions

The company's September-quarter cash-flow statement showed AUD 1.807 million in cash at 30 September 2026. It recorded AUD 616,000 of net operating cash outflows and AUD 510,000 of capitalised exploration spending. Greenwing estimated 1.6 quarters of funding based on its reported expenditure measure. It discussed possible additional capital, option exercises, partnerships and asset transactions, but these alternatives should not be described as secured proceeds unless the relevant arrangement has completed.

AVITA: PermeaDerm Clinical and Economic Findings

AVITA's 18 August 2026 announcement described results from its PermeaDerm-I multicentre randomised study. The primary endpoint concerned product cost per 1% of total body surface area treated. PermeaDerm's mean cost was USD 148.70, compared with USD 497.10 for cadaveric allograft, representing a 70% reported advantage on that metric. The study enrolled 40 patients across 11 US burn centres, and the company reported statistically significant results for its cost endpoint.

The company also reported 95.7% less preparation time for PermeaDerm than for allograft, with similar application time. Approximately 94% of the PermeaDerm group reached at least 95% graft take a week after autografting, while all patients in both groups reached at least 95% wound healing by eight weeks. No adverse events were attributed to PermeaDerm in the trial. The results concern a specific wound-covering comparison rather than the full spectrum of AVITA products or patients.

Different Sectors, Different Watchpoints

Greenwing operates in mineral resource development, where project studies, Commodity markets, permits, testwork and financing arrangements govern the advancement of assets. AVITA operates in regulated healthcare technology, where medical evidence, procurement, approvals, Supply reliability and commercial adoption are relevant. The differences mean that identical-looking share-price gains do not indicate shared Revenue models, comparable balance sheets or similar stages of commercial development.

Risks and Catalysts on Watch

For Greenwing, disclosed upcoming activities include San Jorge testwork, scoping-study progress, negotiations with potential partners and the Que River pre-feasibility study. Its reported funding runway and possible dilution remain notable uncertainties. For AVITA, subsequent product adoption, further clinical evidence, regulatory compliance and commercial disclosures are relevant. Both stocks can experience fluctuations unrelated to a single operational announcement, and neither supplied release establishes a direct explanation for the historical appreciation.

Key Developments Ahead

The two quoted gains create a common historical-price theme, while company updates tell separate stories. Greenwing reported ongoing mineral-project definition and Capital considerations; AVITA disclosed quantified clinical and cost findings for a medical product. The next factual milestones are those reported in future company disclosures, rather than any assumption that prior percentage gains will persist.

FAQs

Q: Which two ASX stocks were quoted with gains near or above 300%?

A: Greenwing Resources (ASX:GW1), at about 300%, and AVITA Medical (ASX:AVH), at 307%.

Q: Are their business activities similar?

A: No. Greenwing develops critical-minerals assets; AVITA supplies therapeutic wound-care technology.

Q: Do their uploaded releases explain the one-year gains?

A: No. The releases document company developments, not a verified causal account of annual price changes.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.